Characterization of the Penetration of the Blood–Brain Barrier by High-Performance Liquid Chromatography (HPLC) Using a Stationary Phase with an Immobilized Artificial Membrane

References

• Carpenter, T. S., D. A. Kirshner, E. Y. Lau, S. E. Wong, J. P. Nilmeier, and F. C. Lightstone. 2014. A method to predict blood-brain barrier permeability of drug-like compounds using molecular dynamics simulations. Biophys. J. 107 (3):630–641. doi:10.1016/j.bpj.2014.06.024.
   PubMed Web of Science ®Google Scholar
• Chekhonin, V. P., V. P. Baklaushev, G. M. Iusubalieva, N. E. Volgina, and O. I. Gurina. 2012. Fundamental and applied aspects of the hematoencephalic barrier research. Vestn. Ross. Akad. Med. Nauk (8):66–78. doi:10.15690/vramn.v67i8.352.
   PubMedGoogle Scholar
• Crivori, P., G. Cruciani, P.-A. Carrupt, and B. Testa. 2000. Predicting blood−brain barrier permeation from three-dimensional molecular structure. J. Med. Chem. 43 (11):2204–16. doi:10.1021/jm990968+.
   PubMed Web of Science ®Google Scholar
• Daniel, W., M. Syrek, L. Janczar, and J. Boksa. 1995. The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats--a comparison with the pharmacokinetics of imipramine. Pol. J. Pharmacol. 47 (2):127–36.
   PubMedGoogle Scholar
• De Vrieze, M., F. Lynen, K. Chen, R. Szucs, and P. Sandra. 2013. Predicting drug penetration across the blood–brain barrier: comparison of micellar liquid chromatography and immobilized artificial membrane liquid chromatography. Anal. Bioanal. Chem. 405 (18):6029–41. doi:10.1007/s00216-013-7015-x.
   PubMed Web of Science ®Google Scholar
• Dolezal, R., O. Soukup, D. Malinak, R. M. L. Savedra, J. Marek, M. Dolezalova, M. Pasdiorova, S. Salajkova, J. Korabecny, J. Honegr, et al. 2016. Towards understanding the mechanism of action of antibacterial N-alkyl-3-hydroxypyridinium salts: Biological activities, molecular modeling and QSAR studies. Eur. J. Med. Chem. 121:699–711. doi:10.1016/j.ejmech.2016.05.058.
   PubMed Web of Science ®Google Scholar
• Ducarme, A., M. Neuwels, S. Goldstein, and R. Massingham. 1998. IAM retention and blood brain barrier penetration. Eur. J. Med. Chem. 33 (3):215–23. doi:10.1016/S0223-5234(98)80011-1.
   Web of Science ®Google Scholar
• Grumetto, L., C. Carpentiero, and F. Barbato. 2012. Lipophilic and electrostatic forces encoded in IAM-HPLC indexes of basic drugs: their role in membrane partition and their relationships with BBB passage data. Eur. J. Pharm. Sci. 45 (5):685–92. doi:10.1016/j.ejps.2012.01.008.
   PubMed Web of Science ®Google Scholar
• Grumetto, L., G. Russo, and F. Barbato. 2016. Immobilized artificial membrane HPLC derived parameters vs PAMPA-BBB data in estimating in situ measured blood-brain barrier permeation of drugs. Mol. Pharm. 13 (8):2808–16. doi:10.1021/acs.molpharmaceut.6b00397.
   PubMed Web of Science ®Google Scholar
• Karasova, J. Z., M. Pohanka, K. Musilek, F. Zemek, and K. Kuca. 2010. Passive diffusion of acetylcholinesterase oxime reactivators through the blood-brain barrier: influence of molecular structure. Toxicol. In Vitro 24 (6):1838–44. doi:10.1016/j.tiv.2010.05.009.
   PubMed Web of Science ®Google Scholar
• Karelson, M., D. Dobchev, T. Tamm, I. Tulp, J. Jänes, K. Tämm, A. Lomaka, D. Savchenko, and G. Karelson. 2008. Correlation of blood-brain penetration and human serum albumin binding with theoretical descriptors. Arkivoc 16:38–60. doi:10.3998/ark.5550190.0009.g05.
   Google Scholar
• Kubinyi, H. 1977. Quantitative structure–activity relationships. 7. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character. J. Med. Chem. 20 (5):625–9. doi:10.1021/jm00215a002.
   PubMed Web of Science ®Google Scholar
• Pardridge, W. M. 2005. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2 (1):3–14. doi:10.1602/neurorx.2.1.3.
   PubMedGoogle Scholar
• Sallee, F. R., and B. G. Pollock. 1990. Clinical pharmacokinetics of imipramine and desipramine. Clin. Pharmacokinet. 18 (5):346–64. doi:10.2165/00003088-199018050-00002.
   PubMed Web of Science ®Google Scholar
• Wang, J. 2009. Comprehensive assessment of ADMET risks in drug discovery. Curr. Pharm. Des. 15 (19):2195–219. doi:10.2174/138161209788682514.
   PubMed Web of Science ®Google Scholar
• Yeung, P. K., J. W. Hubbard, E. D. Korchinski, and K. K. Midha. 1993. Pharmacokinetics of chlorpromazine and key metabolites. Eur. J. Clin. Pharmacol. 45 (6):563–9. doi:10.1007/BF00315316.
   PubMed Web of Science ®Google Scholar
• Yoon, C. H., S. J. Kim, B. S. Shin, K. C. Lee, and S. D. Yoo. 2005. Rapid screening of blood-brain barrier penetration of drugs using the immobilized artificial membrane phosphatidylcholine column chromatography. J. Biomol. Screen. 11 (1):13–20. doi:10.1177/1087057105281656.
   PubMedGoogle Scholar